Pseudomixoma peritoneal: operação citorredutora e quimio-hipertermia intraperitoneal - Relato de dois casos

Ayoub, Jimmy Ali Saadallah; Bolognani, Carlos Eduardo Dainezzi; Bellandi, Detlev Mauri; Meyer, Alberto Monteiro; Ayoub, Ismail

doi:10.1590/s0102-67202012000100016

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prognosis of these patients is poor with a median survival of 6 months after diagnosis. Early diagnosis and identification of patients at high risk of developing metachronous peritoneal carcinomatosis is important, as selected patients may benefit from potentially curative treatments such as cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

A rare sporadic pancreatic desmoid fibromatosis with splenic vein invasion diagnosed by CT scan-guided core needle biopsy: a case report with possible differential diagnosis from metastatic colorectal or renal cancer

Meyer

Szajnbok

Koszka

et al. 2021

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Desmoid tumor is a rare fibroblastic proliferation with a variable and often unpredictable clinical course that arises in the deep soft tissues and is characterized by infiltrative growth with tendency to local recurrence but not to metastasize. A 49-year-old man was referred for a second opinion regarding a pancreatic mass. With a personal neoplastic background of two different tumors, we considered as a high probability of being metastatic of his previous colorectal or renal cancers, in a peritoneal implant. Due to the unclear origin and nature of the mass, we opted for requesting a computed tomography (CT)-guided core needle biopsy that could eventually lead to a surgical and/or chemotherapy treatment. So far, this is the first case of pancreatic desmoid fibromatosis with splenic vein invasion diagnosed by CT scan-guided core needle biopsy. Surgery should be performed by an experienced surgeon as first-line therapy, provided expected surgical morbidity is limited.

show abstract

Section: Discussionmentioning

confidence: 99%